Okonkwo, Adaora
Okonkwo, Adaora was paid $2.78M by Medicaid between Jan 2018 and Dec 2024, across 110 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 22% of everything it billed.
LIBERTYVILLE, IL 60048
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 571 | $11K | |
| 2019 | 530 | $13K | |
| 2020 | 55,822 | $296K | |
| 2021 | 74,484 | $741K | |
| 2022 | 78,363 | $701K | |
| 2023 | 81,293 | $538K | |
| 2024incomplete | 83,939 | $477K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 22% | 10,025 | 8,650 | $598K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 9.4% | 3,435 | 3,309 | $260K |
| 80053 | Comprehensive metabolic panel | 8.6% | 46,712 | 29,619 | $239K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.1% | 7,091 | 6,161 | $170K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.7% | 55,042 | 32,264 | $160K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 4.9% | 3,873 | 3,595 | $137K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 4.1% | 14,618 | 13,636 | $114K |
| 83735 | 3.3% | 24,372 | 12,070 | $90K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.1% | 20,724 | 8,395 | $87K |
| 84484 | 2.0% | 12,874 | 9,770 | $56K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.6% | 8,608 | 7,951 | $46K |
| 87040 | 1.6% | 4,738 | 3,766 | $45K |
98 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 5,123 | $43K |
| 83880 | 1.4% | 3,264 | $39K | |
| 87081 | 1.4% | 13,111 | $38K | |
| 83690 | 1.3% | 10,230 | $36K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.3% | 1,646 | $36K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.3% | 1,639 | $36K |
| 85027 | 1.2% | 11,474 | $33K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.2% | 1,586 | $33K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 1,140 | $31K |
| 83605 | <1% | 5,505 | $27K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,057 | $26K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,098 | $25K |
| 88342 | <1% | 1,546 | $24K | |
| 84100 | <1% | 9,044 | $21K | |
| 85730 | <1% | 6,448 | $21K | |
| 0240U | <1% | 239 | $18K | |
| 85610 | <1% | 8,263 | $17K | |
| 81001 | <1% | 11,112 | $16K | |
| 86850 | <1% | 4,453 | $13K | |
| 85379 | <1% | 3,256 | $13K | |
| 86901 | <1% | 5,689 | $12K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 329 | $12K |
| 86900 | <1% | 5,686 | $9K | |
| 80061 | Lipid panel | <1% | 2,387 | $9K |
| 88307 | <1% | 135 | $9K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 250 | $9K |
| 82803 | <1% | 749 | $8K | |
| 82550 | <1% | 2,623 | $8K | |
| 88304 | <1% | 436 | $8K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 47 | $8K |
| 87088 | <1% | 1,362 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,379 | $7K |
| 84702 | <1% | 1,593 | $7K | |
| 84439 | <1% | 1,550 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 469 | $7K |
| 86140 | <1% | 2,816 | $7K | |
| 87075 | <1% | 889 | $6K | |
| 82728 | <1% | 1,208 | $5K | |
| 82077 | <1% | 356 | $5K | |
| 87070 | <1% | 1,449 | $5K | |
| 87480 | <1% | 367 | $5K | |
| 87510 | <1% | 367 | $5K | |
| 81003 | <1% | 4,503 | $5K | |
| 85018 | <1% | 3,085 | $4K | |
| 87563 | <1% | 324 | $4K | |
| 87660 | <1% | 366 | $3K | |
| 87205 | <1% | 1,639 | $3K | |
| 80143 | <1% | 171 | $3K | |
| 82140 | <1% | 629 | $3K | |
| 82607 | <1% | 469 | $3K | |
| 80179 | <1% | 164 | $3K | |
| 83615 | <1% | 909 | $3K | |
| 82570 | <1% | 951 | $2K | |
| 84703 | <1% | 605 | $2K | |
| 85652 | <1% | 1,561 | $2K | |
| 87641 | <1% | 80 | $2K | |
| 86480 | <1% | 74 | $2K | |
| 85014 | <1% | 1,505 | $2K | |
| 83550 | <1% | 399 | $2K | |
| 81025 | <1% | 641 | $2K | |
| 87340 | <1% | 256 | $2K | |
| 82746 | <1% | 278 | $2K | |
| 80076 | <1% | 323 | $1K | |
| 82248 | <1% | 602 | $1K | |
| 82010 | <1% | 453 | $1K | |
| 82247 | <1% | 484 | $1K | |
| 84300 | <1% | 458 | $962.48 | |
| 84145 | <1% | 353 | $936.05 | |
| 80202 | <1% | 132 | $889.76 | |
| 85049 | <1% | 702 | $840.28 | |
| 84156 | <1% | 678 | $790.12 | |
| 86880 | <1% | 269 | $782.50 | |
| 85048 | <1% | 892 | $766.19 | |
| 88112 | <1% | 53 | $717.38 | |
| 87493 | <1% | 31 | $710.21 | |
| 84132 | <1% | 271 | $621.24 | |
| 87807 | <1% | 121 | $593.54 | |
| 80050 | General health panel | <1% | 32 | $509.25 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 17 | $417.69 |
| 87210 | <1% | 155 | $361.90 | |
| 86706 | <1% | 53 | $323.25 | |
| 86592 | <1% | 144 | $284.70 | |
| 83935 | <1% | 109 | $257.69 | |
| 80074 | <1% | 13 | $250.12 | |
| 87806 | <1% | 26 | $233.82 | |
| 80320 | <1% | 660 | $180.00 | |
| 89051 | <1% | 59 | $171.50 | |
| 83930 | <1% | 65 | $163.10 | |
| 86308 | <1% | 65 | $148.80 | |
| 82150 | <1% | 43 | $137.17 | |
| 84550 | <1% | 59 | $121.67 | |
| 86803 | <1% | 13 | $109.46 | |
| 87147 | <1% | 54 | $95.95 | |
| 86038 | <1% | 13 | $78.65 | |
| 86704 | <1% | 12 | $72.36 | |
| 87077 | <1% | 170 | $25.86 | |
| 84157 | <1% | 14 | $19.40 | |
| 80329 | 0% | 313 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.